Mumbai: Gufic Biosciences, a pioneer in complex injectables with a 54-year legacy, continues to enhance its global manufacturing capabilities and scientific excellence in assisted reproductive technologies (ART). With EU cGMP-approved facilities and a robust pipeline of innovative fertility treatments, Gufic is committed to setting new benchmarks in reproductive healthcare while expanding its footprint across regulated markets.
At the heart of Gufic’s IVF division are three scientifically advanced therapies:
•Supergraf – an ultra-purified HMG formulation developed through advanced purification techniques, ensuring superior efficacy in ovarian stimulation and enhanced safety for IVF patients.
•Puregraf – a leading gonadotropin brand trusted by fertility specialists, reinforcing Gufic’s commitment to high-purity, clinically validated fertility solutions.
•Guficin Alpha – a first-of-its-kind therapy for Recurrent Implantation Failure (RIF), designed to improve embryo implantation success rates. With no comparable alternative currently available, Guficin Alpha is set to revolutionize treatment approaches in IVF.
With its EU cGMP-approved facilities and world-class manufacturing infrastructure, including the recently commissioned Indore plant, Gufic is well-positioned to meet the growing global demand for high-quality reproductive health solutions. The company’s focus on clinical validation, scientific research, and real-world data ensures that its fertility portfolio remains at the forefront of innovation.
By combining its five-decade legacy with cutting-edge manufacturing, regulatory excellence, and strategic international expansion, Gufic Biosciences remains a trusted global partner in fertility treatments, delivering accessible, high-quality, and evidence-based solutions for clinicians and patients worldwide.
